IDH2 and acute myeloid leukemia: For a panel of primary CD34+ and AML samples we observed a consistent switch to glycolysis as the major source of ATP when treated with IACS-010759, irrespective of IDH mutation status, although this was associated with a high degree of variability in the proportion of glycolysis/OXPHOS observed across untreated samples (Fig. 4d, Supplementary Fig. 7).